News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,519 Results
Type
Article (739)
Company Profile (2)
Press Release (778)
Section
Business (486)
Career Advice (1)
Deals (63)
Drug Delivery (1)
Drug Development (823)
FDA (97)
Job Trends (140)
News (1019)
Policy (354)
Tag
Academia (26)
Alliances (176)
Alzheimer's disease (1)
Antibody-drug conjugate (ADC) (9)
Approvals (89)
Artificial intelligence (6)
Bankruptcy (1)
Best Places to Work (136)
BIOSECURE Act (1)
Biosimilars (1)
Biotechnology (2)
Brain cancer (1)
Breast cancer (7)
Cancer (41)
Cardiovascular disease (2)
Career advice (1)
CAR-T (1)
CDC (5)
Cell therapy (5)
Clinical research (299)
Collaboration (7)
COVID-19 (501)
C-suite (3)
Cystic fibrosis (1)
Data (6)
Denatured (3)
Diagnostics (46)
Drug discovery (2)
Drug pricing (1)
Duchenne muscular dystrophy (1)
Earnings (157)
Editorial (3)
Events (132)
Executive appointments (1)
FDA (101)
Funding (5)
Gene editing (2)
Gene therapy (5)
GLP-1 (17)
Government (188)
Guidances (1)
Healthcare (129)
Immunology and inflammation (3)
Immuno-oncology (2)
Infectious disease (505)
Influenza (2)
IPO (32)
IRA (2)
Job creations (11)
Job search strategy (1)
Layoffs (5)
Legal (47)
Lung cancer (15)
Manufacturing (4)
Medical device (14)
Medtech (14)
Mergers & acquisitions (34)
Metabolic disorders (9)
Neuroscience (1)
NextGen: Class of 2025 (9)
Non-profit (8)
Obesity (8)
Opinion (3)
Pancreatic cancer (1)
Patents (5)
Patient recruitment (1)
People (121)
Phase I (153)
Phase II (176)
Phase III (192)
Pipeline (15)
Policy (12)
Postmarket research (2)
Preclinical (58)
Prostate cancer (1)
Psychedelics (2)
Radiopharmaceuticals (2)
Rare diseases (6)
Real estate (14)
Regulatory (176)
Research institute (39)
RSV (3)
Series A (1)
Series B (1)
Sickle cell disease (1)
Special edition (2)
Startups (10)
Tariffs (1)
The Weekly (9)
Vaccines (178)
Venture capital (1)
Weight loss (3)
Date
Last 7 days (2)
Last 30 days (9)
Last 365 days (143)
2025 (69)
2024 (167)
2023 (165)
2022 (293)
2021 (354)
2020 (342)
2019 (43)
2018 (29)
2017 (15)
2016 (14)
2015 (14)
2014 (3)
2013 (4)
2012 (7)
Location
Africa (14)
Asia (146)
Australia (7)
California (2)
Canada (3)
China (9)
Europe (658)
Florida (1)
Indiana (1)
Maryland (5)
Massachusetts (10)
New Jersey (6)
New York (9)
Northern California (1)
Ohio (1)
South America (5)
United States (36)
1,519 Results for "biontech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
BioNTech Swallows Vaccine Rival CureVac in $1.25B All-Stock Acquisition
BioNTech will get CureVac’s early-stage cancer assets, including its mRNA-based glioblastoma therapy currently in Phase I development. CureVac had previously sued BioNTech for copyright infringement related to mRNA vaccine technology.
June 12, 2025
·
3 min read
·
Tristan Manalac
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company.
June 18, 2025
·
4 min read
·
Nick Paul Taylor
Earnings
BioNTech’s Ambitious PD-L1/VEGF Plans Currently Rely on Chinese Manufacturing
BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a diversified supply chain, executives said during the company’s Q1 investor call.
May 5, 2025
·
3 min read
·
Tristan Manalac
Pipeline
BioNTech Strives to Become Commercial ‘Powerhouse’ While Maintaining Humility
Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she will oversee BioNTech’s transition from a COVID-19 vaccine maker to an “end-to-end organizational oncology powerhouse.”
January 16, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
June 12, 2025
·
17 min read
Cancer
BioNTech’s Bispecific Elicits Treatment Response in Majority of SCLC Patients
BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.
March 28, 2025
·
2 min read
·
Tristan Manalac
Deals
BMS Commits up to $11B+ To Work With BioNTech on Solid Tumor Bispecific
Bristol Myers Squibb is dropping at least $3.5 billion to jointly develop the bispecific antibody, which will race with Summit Therapeutics, Merck and Pfizer in the crowded PD-1/PD-L1xVEGF space.
June 2, 2025
·
2 min read
·
David Adam
Press Releases
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
May 28, 2025
·
11 min read
Press Releases
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
May 5, 2025
·
24 min read
Vaccines
FDA Pauses Study of BioNTech’s Malaria Shot as Problems for Vaccine Space Mount
The vaccine space has been battered by strong headwinds in recent weeks, including high-level disruptions to FDA and CDC advisory committee meetings.
March 5, 2025
·
2 min read
·
Tristan Manalac
1 of 152
Next
